Skip Navigation

European Heart Journal 2000 21(18):1530-1536; doi:10.1053/euhj.1999.2035
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ronner, E
Right arrow Articles by Simoons, M.L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ronner, E
Right arrow Articles by Simoons, M.L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind study

E Ronnera, H.A.M van Kesterenb, P Zijnenc, E Altmannd, P.G Molhoeke, L.R van der Wiekenf, C.A Cuffie-Jacksong, K.L Neuhaush and M.L Simoonsa,f1

a Thoraxcenter and Cardialysis, Rotterdam, The Netherlands
b Maria Ziekenhuis, Tilburg, The Netherlands
c St. Elisabeth Ziekenhuis, Tilburg, The Netherlands
d Krankenhaus Dresden-Friedrichstadt, Dresden, Germany
e Medisch Spectrum Twente, Enschede, The Netherlands
f Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
g Schering-Plough Research, Kenilworth, USA
h Karl L. Neuhaus, Stadtische Kliniken, Kassel, Germany

Received September 15, 1999; accepted December 1, 1999

Abstract

Aims Thrombolytic therapy restores coronary patency in patients with acute myocardial infarction, although normal perfusion (TIMI 3 flow) is not achieved in all patients. In an attempt to improve TIMI 3 flow, a combination of full-dose streptokinase, aspirin and escalating dosages of a platelet glycoprotein IIb/IIIa receptor blocker, eptifibatide, vs placebo were tested.

Methods and Results A bolus of 180µg.kg–1of eptifibatide was administered in each group, followed by a 72h continuous infusion of 0·75 (44 patients), 1·33 (n=45) and 2·00µg.kg–1.min–1(n=30); 62 patients received placebo. Normal perfusion (TIMI 3 flow) at 90min was observed in 31% of placebo patients compared to 46, 42 and 45% in the ascending eptifibatide groups (44% for combined eptifibatide groups, P=0·07). Patency (TIMI 2 and 3 flow combined) increased from 61% (placebo) to 78% for the combined eptifibatide groups (P=0·02). Reocclusion was infrequent. No differences were observed in TIMI flow grades among eptifibatide groups. Major and minor bleeding was increased and occurred mainly at the arterial puncture site.

Conclusion A combination of full dose streptokinase with different eptifibatide regimens enhanced coronary perfusion, but bleeding risk was excessive. Additional trials are needed with different dosage regimens to determine the optimal combination of fibrinolytic agents and platelet glycoprotein IIb/IIIa receptor blockers.

Key Words: Myocardial infarction, platelet aggregation inhibitors, thrombolysis, angiography, streptokinase, eptifibatide

f1 Correspondence: Prof. Maarten L. Simoons, Thoraxcenter, Bd 434, Academisch Ziekenhuis Dijkzigt, Dr. Molenwaterplain 40, 3015 GD, Rotterdam, The Netherlands.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 708S - 775S.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Part 5: Acute Coronary Syndromes
Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72.
[Full Text] [PDF]

Home page
 JAMAHome page
G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol
Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials
JAMA, April 13, 2005; 293(14): 1759 - 1765.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. P. Giugliano, M. T. Roe, R. A. Harrington, C. M. Gibson, U. Zeymer, F. Van de Werf, K. W. Baran, H.-P. Hobbach, L. H. Woodlief, K. L. Hannan, et al.
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic urial
J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1251 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M.L. Simoons, M. Krzeminska-Pakula, A. Alonso, S.G. Goodman, A. Kali, U. Loos, F. Gosset, V. Louer, and F. Bigonzi
Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study
Eur. Heart J., August 2, 2002; 23(16): 1282 - 1290.
[Abstract] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
S. M. Inverso
Combination Glycoprotein IIb/IIIa Receptor Antagonists With Thrombolytics in Acute Myocardial Infarction
Journal of Pharmacy Practice, August 1, 2002; 15(4): 344 - 355.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
S. J. Brener, U. Zeymer, A. A. J. Adgey, T. R. Vrobel, S. G. Ellis, K.-L. Neuhaus, N. Juran, T. B. Ivanc, E. M. Ohman, J. Strony, et al.
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial
J. Am. Coll. Cardiol., February 6, 2002; 39(3): 377 - 386.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. W. Armstrong and D. Collen
Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 2
Circulation, June 19, 2001; 103(24): 2987 - 2992.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Wilcox
Patency, perfusion, performance--the desirable triplets of combination thrombolytic therapy
Eur. Heart J., September 2, 2000; 21(18): 1495 - 1497.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.